Moderna's (NASDAQ:MRNA) mRNA-1647, its vaccine asset for cytomegalovirus (CMV), may not yield positive interim phase 3 data ...

There was no significant difference between HT (27.8%) and HC (30.0%) regarding frequency of individuals positive for CMV-specific IgG (Table 1). One HT patient and three HC were concomitantly ...

“We are pleased with these positive outcomes of the initial preclinical studies in our CMV vaccine program, demonstrating our AI-Immunology™ platform’s ability to identify novel antigens to ...

Patients who demonstrate immunity to CMV (CMV IgG-positive) could be monitored for CMV infection rather than receive prophylaxis with valganciclovir, and fungal infection could also be treated if ...

“We are pleased with these positive outcomes of the initial preclinical studies in our CMV vaccine program, demonstrating our AI-Immunology™ platform’s ability to identify novel ...

No approved CMV vaccine exists today COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ ...

About cytomegalovirus (CMV) About 1 in 200 babies is born with congenital CMV infection. About 1 in 5 babies with the infection will have congenital disabilities or other long-term health problems.